Phase I/II ARROW trial results show that pralsetinib, a highly selective RET inhibitor, was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type.
Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer.
